EFFORT: Phase II Study of the WEE1 Inhibitor Adavosertib ± Olaparib in PARPi-Resistant Ovarian Cancer

June 4-8, 2021; Online at https://conferences.asco.org/am
Adavosertib with or without olaparib demonstrated clinical activity with a manageable toxicity profile in patients with PARPi-resistant ovarian cancer, regardless of BRCA status.
Format: Microsoft PowerPoint (.ppt)
File Size: 400 KB
Released: June 8, 2021


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.

Related Content

Downloadable slideset updated with highlights of key gynecologic oncology studies presented at conferences throughout 2021, from Clinical Care Options (CCO)

Jubilee Brown, MD Melissa M. Hardesty, MD, MPH person default Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD Ursula Matulonis, MD David Scott Miller, MD, FACOG, FACS Released: September 15, 2021

Gain key clinical insights quickly with this short slideset from CCO on the latest treatment, challenges and future directions for the management of ovarian cancer using PARPi.

Nicoletta Colombo, MD person default Philipp Harter, MD, PhD person default Alexandra Leary, MD, PhD Released: September 10, 2021

Downloadable slideset on current advances in PARP inhibition in ovarian cancer from Clinical Care Options (CCO)

Nicoletta Colombo, MD Released: September 3, 2021

Downloadable slideset on a clinical case of PARP inhibition in a patient with ovarian cancer from Clinical Care Options (CCO)

person default Philipp Harter, MD, PhD Released: September 3, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.